“We are excited to be able to offer our team Matt’s vast strategic and deep operational experience as we prepare the platform for our clinical adventure,” said Geoff McDonough, M.D., president and CEO of Generation Bio.
Dr. Norkunas recently served as CHIEF Financial Officer of SomaLogic, Inc., a Colorado-founded biogeneration apple that uses patented protein studies to assess disease fitness and risk. Previously, Dr. Norkunas, a senior equity analyst at Marsico Capital Management, was Apple’s number one fitness specialist. Dr. Norkunas began his career as an exercise anesthetist. They gave him his B.A. S t. Mary’s College of Maryland, your Ph.D. University of Maryland School of Medicine and its MBA from Columbia Business School.
“I have long believed that precision medicine has the strength to transform our world and I am very pleased that this team is emerging in some way to do it on a large scale,” Dr. Norkunas said. “Generation Bio’s non-viral form of plats is designed to make the success of genetic cure greater for other Americans living with rare and widespread diseases. I advance to help shape and help the company’s expansion.”
Generation Bio is a state-of-the-art genetic apple that focuses on creating a new elegance of non-viral genetic cure to produce sustainable and retractable remedies for other humans with rare and widespread diseases. The non-viral form of the combined apple incorporates an exclusive high-capacity DNA design called closed-ended DNA or CDNA; A formula for administering lipid nanoparticles targeting cells, or ctLNP; and an established and scalable production procedure without capsaside. The platshape shape is designed to allow for multi-year durability from a single dose of CDNA, and to allow titration and rebound if necessary. CtLNP is designed to produce giant genetic loads, adding various genes, to precise tdisorders to respond to a wide variety of indications. The efficient and scalable production procedure of the compatible apple misidentirectionally supports Generation Bio to make the success of genetic healing greater for more people, living with more diseases, in more places in the world.
For more information, visit www.generationbio.com.
Contact:
Investors Monique Allaire THRUST Communications straté[email protected] 617-895-9511